Medical Accounts Payable vs Other Current Liab Analysis

MVP Stock

0.42 0.01 2.33%

Medical Developments financial indicator trend analysis is infinitely more than just investigating Medical Developments recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Medical Developments is a good investment. Please check the relationship between Medical Developments Accounts Payable and its Other Current Liab accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Medical Developments International. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Accounts Payable vs Other Current Liab

Accounts Payable vs Other Current Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Medical Developments Accounts Payable account and Other Current Liab. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Medical Developments' Accounts Payable and Other Current Liab is -0.22. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Other Current Liab in the same time period over historical financial statements of Medical Developments International, assuming nothing else is changed. The correlation between historical values of Medical Developments' Accounts Payable and Other Current Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Medical Developments International are associated (or correlated) with its Other Current Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Current Liab has no effect on the direction of Accounts Payable i.e., Medical Developments' Accounts Payable and Other Current Liab go up and down completely randomly.

Correlation Coefficient

-0.22

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Accounts Payable

An accounting item on the balance sheet that represents Medical Developments obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Medical Developments are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Other Current Liab

Most indicators from Medical Developments' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Medical Developments current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Medical Developments International. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

At this time, Medical Developments' Selling General Administrative is comparatively stable compared to the past year. Tax Provision is likely to gain to about 8.5 M in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 20.4 M in 2024.

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	2.9M	3.1M	3.4M	3.1M
Interest Income	45K	657K	402K	243.6K

Reconciled Depreciation Interest Income

Medical Developments fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Other Current Liab	Other Liab	Current Deferred Revenue
Total Assets		0.04	0.84	0.94	0.9	-0.84	0.67	0.89	0.91	0.89	0.74	0.81	0.71	0.05	0.72	0.7	0.05	0.88	0.75	0.95	-0.51	0.39	0.61	0.43	0.67	0.41
Short Long Term Debt Total	0.04		-0.02	-0.03	0.19	0.31	0.02	-0.12	0.12	-0.12	-0.06	-0.03	-0.01	0.01	0.27	0.08	-0.24	0.12	0.11	-0.11	0.1	0.1	0.0	0.14	-0.04	0.07
Total Current Liabilities	0.84	-0.02		0.84	0.74	-0.61	0.8	0.65	0.75	0.65	0.81	0.67	0.78	-0.01	0.42	0.7	0.35	0.68	0.69	0.8	-0.43	0.32	0.61	0.23	0.37	0.35
Total Stockholder Equity	0.94	-0.03	0.84		0.83	-0.86	0.76	0.9	0.87	0.9	0.77	0.79	0.81	-0.01	0.58	0.74	-0.01	0.67	0.79	0.96	-0.41	0.4	0.71	0.21	0.42	0.19
Property Plant And Equipment Net	0.9	0.19	0.74	0.83		-0.67	0.75	0.73	0.84	0.73	0.85	0.91	0.76	-0.31	0.68	0.87	-0.06	0.8	0.91	0.82	-0.56	0.65	0.78	0.37	0.55	0.49
Net Debt	-0.84	0.31	-0.61	-0.86	-0.67		-0.48	-0.98	-0.68	-0.98	-0.59	-0.73	-0.56	-0.01	-0.48	-0.53	-0.04	-0.63	-0.61	-0.94	0.37	-0.29	-0.56	-0.3	-0.57	-0.19
Accounts Payable	0.67	0.02	0.8	0.76	0.75	-0.48		0.49	0.72	0.49	0.86	0.77	0.86	-0.44	0.39	0.91	0.06	0.4	0.89	0.64	-0.33	0.62	0.88	-0.22	0.0	0.08
Cash	0.89	-0.12	0.65	0.9	0.73	-0.98	0.49		0.74	1.0	0.59	0.74	0.59	0.06	0.56	0.55	0.0	0.69	0.64	0.97	-0.37	0.29	0.55	0.36	0.61	0.22
Non Current Assets Total	0.91	0.12	0.75	0.87	0.84	-0.68	0.72	0.74		0.74	0.6	0.73	0.68	0.03	0.88	0.73	-0.02	0.78	0.73	0.81	-0.36	0.52	0.6	0.21	0.5	0.24
Cash And Short Term Investments	0.89	-0.12	0.65	0.9	0.73	-0.98	0.49	1.0	0.74		0.59	0.73	0.59	0.06	0.56	0.54	0.0	0.69	0.64	0.97	-0.36	0.29	0.55	0.36	0.61	0.22
Net Receivables	0.74	-0.06	0.81	0.77	0.85	-0.59	0.86	0.59	0.6	0.59		0.84	0.8	-0.45	0.26	0.85	0.05	0.55	0.88	0.72	-0.51	0.52	0.84	0.17	0.27	0.37
Common Stock Total Equity	0.81	-0.03	0.67	0.79	0.91	-0.73	0.77	0.74	0.73	0.73	0.84		0.82	-0.52	0.55	0.91	-0.08	0.67	0.92	0.8	-0.44	0.77	0.9	0.14	0.44	0.31
Common Stock Shares Outstanding	0.71	-0.01	0.78	0.81	0.76	-0.56	0.86	0.59	0.68	0.59	0.8	0.82		-0.35	0.35	0.87	-0.01	0.43	0.86	0.73	-0.35	0.66	0.87	-0.09	0.1	0.14
Short Term Investments	0.05	0.01	-0.01	-0.01	-0.31	-0.01	-0.44	0.06	0.03	0.06	-0.45	-0.52	-0.35		0.09	-0.62	0.04	0.12	-0.56	0.01	0.1	-0.73	-0.69	0.35	0.27	0.0
Non Current Liabilities Total	0.72	0.27	0.42	0.58	0.68	-0.48	0.39	0.56	0.88	0.56	0.26	0.55	0.35	0.09		0.5	-0.08	0.77	0.5	0.57	-0.25	0.46	0.33	0.27	0.6	0.24
Inventory	0.7	0.08	0.7	0.74	0.87	-0.53	0.91	0.55	0.73	0.54	0.85	0.91	0.87	-0.62	0.5		0.04	0.51	0.98	0.67	-0.42	0.82	0.96	-0.07	0.16	0.22
Other Current Assets	0.05	-0.24	0.35	-0.01	-0.06	-0.04	0.06	0.0	-0.02	0.0	0.05	-0.08	-0.01	0.04	-0.08	0.04		0.14	-0.05	0.09	-0.28	-0.09	-0.04	0.14	0.11	0.29
Total Liab	0.88	0.12	0.68	0.67	0.8	-0.63	0.4	0.69	0.78	0.69	0.55	0.67	0.43	0.12	0.77	0.51	0.14		0.52	0.74	-0.55	0.3	0.34	0.65	0.89	0.65
Property Plant And Equipment Gross	0.75	0.11	0.69	0.79	0.91	-0.61	0.89	0.64	0.73	0.64	0.88	0.92	0.86	-0.56	0.5	0.98	-0.05	0.52		0.74	-0.43	0.77	0.96	-0.01	0.21	0.22
Total Current Assets	0.95	-0.11	0.8	0.96	0.82	-0.94	0.64	0.97	0.81	0.97	0.72	0.8	0.73	0.01	0.57	0.67	0.09	0.74	0.74		-0.45	0.36	0.65	0.34	0.58	0.29
Short Term Debt	-0.51	0.1	-0.43	-0.41	-0.56	0.37	-0.33	-0.37	-0.36	-0.36	-0.51	-0.44	-0.35	0.1	-0.25	-0.42	-0.28	-0.55	-0.43	-0.45		-0.21	-0.33	-0.51	-0.5	-0.81
Intangible Assets	0.39	0.1	0.32	0.4	0.65	-0.29	0.62	0.29	0.52	0.29	0.52	0.77	0.66	-0.73	0.46	0.82	-0.09	0.3	0.77	0.36	-0.21		0.8	-0.14	0.05	0.16
Common Stock	0.61	0.0	0.61	0.71	0.78	-0.56	0.88	0.55	0.6	0.55	0.84	0.9	0.87	-0.69	0.33	0.96	-0.04	0.34	0.96	0.65	-0.33	0.8		-0.19	0.03	0.08
Other Current Liab	0.43	0.14	0.23	0.21	0.37	-0.3	-0.22	0.36	0.21	0.36	0.17	0.14	-0.09	0.35	0.27	-0.07	0.14	0.65	-0.01	0.34	-0.51	-0.14	-0.19		0.79	0.79
Other Liab	0.67	-0.04	0.37	0.42	0.55	-0.57	0.0	0.61	0.5	0.61	0.27	0.44	0.1	0.27	0.6	0.16	0.11	0.89	0.21	0.58	-0.5	0.05	0.03	0.79		0.67
Current Deferred Revenue	0.41	0.07	0.35	0.19	0.49	-0.19	0.08	0.22	0.24	0.22	0.37	0.31	0.14	0.0	0.24	0.22	0.29	0.65	0.22	0.29	-0.81	0.16	0.08	0.79	0.67

Click cells to compare fundamentals

Medical Developments Account Relationship Matchups

Medical Developments fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	94.9M	100.2M	101.4M	109.5M	63.8M	44.5M
Short Long Term Debt Total	3.4M	3.0M	2.8M	2.6M	2.3M	2.7M
Total Current Liabilities	8.2M	7.0M	10.5M	15.5M	9.5M	5.1M
Total Stockholder Equity	43.3M	68.3M	57.3M	81.3M	45.7M	28.2M
Property Plant And Equipment Net	11.8M	11.7M	11.6M	12.1M	10.2M	10.7M
Net Debt	(12.2M)	(33.2M)	(17.6M)	(22.1M)	(7.4M)	(7.8M)
Accounts Payable	3.8M	3.3M	9.4M	13.3M	8.3M	8.7M
Cash	15.5M	36.3M	20.4M	24.7M	9.7M	7.9M
Non Current Assets Total	68.9M	52.8M	67.0M	66.7M	33.0M	24.1M
Cash And Short Term Investments	15.5M	36.3M	20.4M	24.7M	9.7M	7.9M
Net Receivables	4.1M	5.0M	6.2M	8.9M	7.1M	7.4M
Common Stock Shares Outstanding	67.0M	69.6M	72.4M	84.3M	88.6M	67.3M
Liabilities And Stockholders Equity	94.9M	100.2M	101.4M	109.5M	59.2M	44.6M
Non Current Liabilities Total	43.3M	24.9M	33.6M	12.6M	3.9M	7.1M
Inventory	5.9M	5.7M	7.1M	8.4M	8.8M	9.2M
Other Current Assets	416K	397K	620K	791K	565K	482.7K
Total Liab	51.5M	31.9M	44.1M	28.2M	18.0M	16.3M
Property Plant And Equipment Gross	11.8M	18.9M	20.1M	22.3M	22.7M	23.8M
Total Current Assets	26.0M	47.4M	34.4M	42.8M	26.1M	15.1M
Short Term Debt	417K	337K	348K	352K	371K	494.4K
Intangible Assets	16.1M	8.2M	8.0M	8.5M	19.0M	20.0M
Common Stock	41.0M	76.9M	77.0M	105.7M	121.6M	127.7M
Other Current Liab	4.0M	3.3M	683K	1.6M	639K	607.1K
Other Liab	30.3M	22.2M	22.0M	2.2M	2.6M	2.4M
Current Deferred Revenue	2.4M	68K	82K	283K	325.5K	508.4K
Retained Earnings	427K	(12.1M)	(24.5M)	(30.2M)	(62.9M)	(59.7M)
Other Assets	36.0M	35.1M	40.7M	8.1M	4.6M	4.4M
Accumulated Other Comprehensive Income	2.0M	3.5M	4.9M	5.7M	2.9M	3.0M
Property Plant Equipment	11.8M	11.7M	11.6M	12.1M	13.9M	14.6M
Non Currrent Assets Other	28.8M	30.6M	32.7M	29.9M	(3.0M)	(2.9M)
Net Tangible Assets	32.3M	62.3M	51.7M	75.7M	87.1M	91.4M
Deferred Long Term Liab	33.9M	32.8M	35.1M	32.7M	37.6M	24.5M
Long Term Debt Total	2.9M	2.7M	2.5M	2.2M	2.5M	2.6M
Net Invested Capital	43.4M	68.3M	57.3M	81.3M	45.7M	54.1M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Medical Stock Analysis

When running Medical Developments' price analysis, check to measure Medical Developments' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medical Developments is operating at the current time. Most of Medical Developments' value examination focuses on studying past and present price action to predict the probability of Medical Developments' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medical Developments' price. Additionally, you may evaluate how the addition of Medical Developments to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC